CUE (Cue Biopharma) Institutional Ownership: 20.11% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CUE Cue Biopharma Inc CUE
63 GF Score
Price $29.65
GF Value $62.74
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Institutional Ownership?

Cue Biopharma CUE -5.74% 63 Institutional Ownership is 20.11% as of Jul. 15, 2026. GuruFocus rates CUE with a GF Score™ of 63/100 and a GF Value™ of $62.74 (Possible Value Trap). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cue Biopharma's institutional ownership is 20.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cue Biopharma's Insider Ownership is 69.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cue Biopharma's Float Percentage Of Total Shares Outstanding is 91.77%.

Cue Biopharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Institutional Ownership Chart

Cue Biopharma Historical Data

The historical data trend for Cue Biopharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 6.11 6.06 5.97 4.88 4.88 4.88 4.57 5.93 6.04 4.99
CUE
63GF Score
Cue Biopharma Inc CUE
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 20.11% mean?
Cue Biopharma (CUE) has a Institutional Ownership of 20.11% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Institutional Ownership too high?
Cue Biopharma's current Institutional Ownership is 20.11%. Overall, Cue Biopharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Institutional Ownership compare to ALPS and AARD?
Cue Biopharma's Institutional Ownership of 20.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Institutional Ownership is 20.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.74, compared to a current price of $29.65 — trading 52.7% below its estimated fair value. The current Institutional Ownership is 20.11%. Cue Biopharma's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Institutional Ownership is 20.11% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $29.65 is trading 52.7% below its estimated GF Value™ of $62.74. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Institutional Ownership: 20.11%
  • GF Value™: $62.74 vs. price of $29.65 (52.7% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
63GF Score

Get the complete analysis for CUE

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.65
Price
$62.74
GF Value